What is immunotherapy? Immunotherapy is a type of cancer treatment that helps the immune system recognize, attack, or control cancer cells. The immune system normally protects the body from infections and abnormal cells, but cancer can sometimes hide from immune defenses or weaken the body’s response. Immunotherapy works by boosting immune activity, removing signals that stop immune cells from attacking, or adding lab-made immune tools that target cancer more precisely.

Understanding immunotherapy can help patients and families know why this treatment is different from chemotherapy, radiation, or surgery. Some types include immune checkpoint inhibitors, CAR T-cell therapy, monoclonal antibodies, cancer vaccines, cytokines, and immune system modulators.

Immunotherapy is not used for every cancer, and it does not work the same way for every person. This article explains seven things to know about immunotherapy, including how it works, who may receive it, possible side effects, and what patients should ask before starting treatment.

7 Critical Facts About Immunotherapy for Cancer

The seven critical facts about immunotherapy for cancer encompass its core mechanism, the major types of treatment, its comparison to chemotherapy, its most successful applications by cancer type, its potential as a cure, its unique side effect profile, and the lasting nature of its benefits. Understanding these key points is essential for appreciating both the revolutionary potential and the practical realities of using the immune system to combat cancer.

To understand better, the following sections will explore each of these seven facts in detail, providing a clear and comprehensive picture of how immunotherapy is reshaping the landscape of cancer treatment.

The Core Mechanism: Releasing the Immune System’s Brakes

To understand what is immunotherapy, it is best to look at it as an indirect approach to fighting cancer. Traditional treatments like chemotherapy and radiation attack tumors directly by killing fast-growing cells. In contrast, immunotherapy focuses entirely on the patient’s own immune system, empowering it to recognize, track down, and eliminate cancer cells naturally.

The human immune system relies on white blood cells called T-cells to constantly patrol the body and destroy abnormal cells. However, cancer cells are highly adaptive and often develop ways to hide from these defenses. They do this by exploiting immune checkpoints, such as the PD-1 and CTLA-4 pathways, which normally act as brakes to prevent the immune system from attacking healthy tissues.

Cancer cells produce corresponding proteins, like PD-L1, that send a “do not attack” signal to T-cells. When answering what is immunotherapy, a major component involves checkpoint inhibitors—specialized drugs that block these deceptive signals. By cutting off this communication, the treatment releases the brakes on the immune system, allowing T-cells to see the cancer as a threat and mount a powerful defense.

The Four Primary Categories of Therapeutic Intervention

Modern oncology uses four primary types of immunotherapy, each using a different strategy to help the immune system fight cancer:

                  [Immunotherapy Therapeutic Classification]
                                      │
     ┌───────────────────┬────────────┴────────────┬───────────────────┐
     ▼                   ▼                         ▼                   ▼
[Checkpoint Inhibitors] [Adoptive Cell Therapy]   [Monoclonal Antibodies] [Treatment Vaccines]
 ├── Pembrolizumab       ├── CAR T-Cell Protocols  ├── Lab-Engineered mAbs ├── Sipuleucel-T
 └── Releases T-cell     └── Re-engineered         └── Marks tumors for    └── Trains defense
     brakes                  patient cells             destruction             against antigens

Immune Checkpoint Inhibitors: As the most widely used form of this therapy, these monoclonal antibodies release the immune system’s brakes. Medications like pembrolizumab and nivolumab are frequently used to treat melanoma, lung cancer, and kidney cancer.

Adoptive Cell Therapy (CAR T-Cell Therapy): This highly personalized treatment involves extracting a patient’s own T-cells and genetically engineering them in a laboratory to produce Chimeric Antigen Receptors (CARs) on their surface. When these modified cells are returned to the patient’s blood, they are uniquely equipped to find and destroy specific blood cancers, such as acute lymphoblastic leukemia and B-cell lymphomas.

Monoclonal Antibodies (mAbs): These lab-designed proteins mimic the antibodies the body produces naturally. Some act as markers that attach to cancer cells, making them more visible to passing immune cells. Others are joined with chemotherapy drugs or radiation particles, delivering toxic treatments directly to the tumor while protecting surrounding healthy tissue.

Cancer Treatment Vaccines: Unlike preventative vaccines that protect against viruses, these are therapeutic treatments given to patients who already have cancer. They work by introducing cancer-specific antigens into the body, training the immune system to find and destroy cells carrying those markers. For example, Sipuleucel-T is an approved vaccine used to treat advanced prostate cancer.

Comparing Philosophies: Immunotherapy vs. Chemotherapy

Immunotherapy and chemotherapy represent two fundamentally different approaches to cancer treatment, from how they work to their side effects and long-term results.

Successful Applications and High-Mutation Malignancies

Immunotherapy is not equally effective against all types of cancer. It works best against highly immunogenic tumors—those that are easily seen and targeted by the immune system. Cancers with a high tumor mutational burden (TMB) produce many abnormal proteins, known as neoantigens, which make them stand out as foreign to circulating T-cells.

[High UV or Carcinogen Mutation Load] ──► Elevated Neoantigen Production ──► High Immunogenicity ──► Enhanced Immunotherapy Success

Advanced melanoma was once considered almost uniformly fatal, but checkpoint inhibitors targeting CTLA-4 and PD-1 have significantly improved long-term survival rates. Because melanoma cells carry many mutations caused by UV radiation damage, they are prime targets for an immune-driven attack.

Similarly, non-small cell lung cancer (NSCLC)—especially tumors that produce high levels of the PD-L1 protein—is now frequently treated with checkpoint inhibitors as a first-line therapy, either on their own or alongside traditional chemotherapy.

This treatment has also become a standard of care for renal cell carcinoma, a type of kidney cancer that historically responded poorly to standard chemotherapy. Additionally, it is highly effective against bladder cancer and tumors with specific genetic features, like mismatch repair deficiency (dMMR), which cause a high number of mutations regardless of where the cancer started in the body.

The Realities of a Functional Cure

While immunotherapy has significantly changed expectations for cancer survival, it is not a universal cure. A true medical cure requires completely and permanently removing all traces of a disease from the body, which remains a very high bar in advanced cancer care.

Instead, for a subset of patients, this therapy can lead to exceptionally long remissions. This state of long-term balance is what oncologists often refer to as a functional cure.

[Traditional Definitive Cure] ──► Complete and permanent removal of all cancer cells from the body
[Functional Immunotherapy Cure] ──► Residual cancer cells exist but are permanently kept in check by the immune system

The success of these treatments varies from person to person and depends on specific biomarkers, the type of cancer, and individual biological factors. While some patients experience dramatic, long-lasting remissions that continue for years after stopping treatment, others may see no response or can develop a resistance to the therapy over time.

For many individuals facing advanced stages of disease, the clinical goal shifts from finding a definitive cure to managing the cancer as a chronic condition, allowing patients to maintain a good quality of life over the long term.

Managing Immune-Related Adverse Events (irAEs)

Because of the way these treatments work, they come with a unique set of side effects known as immune-related adverse events (irAEs). By releasing the brakes on the immune system, the therapy can sometimes cause overactivated T-cells to mistake healthy organs for foreign threats, triggering autoimmune-like inflammation.

                        [Systemic Inflammatory Presentations]
                                          │
     ┌────────────────────────────────────┼────────────────────────────────────┐
     ▼                                    ▼                                    ▼
[Dermatological Tissues]              [Gastrointestinal Tract]             [Endocrine Gland Axis]
 ├── Pruritus & severe itching         ├── Accelerated Colitis              ├── Permanent Hypothyroidism
 └── Intense local dermatitis rashes   └── Severe abdominal pain/diarrhea   └── Chronic adrenal insufficiency

These inflammatory side effects can occur in almost any organ system, but they most commonly affect the skin, gastrointestinal tract, and endocrine glands. Mild cases are typically managed by temporarily pausing the therapy or providing supportive care.

However, severe flares require high-dose corticosteroids, like prednisone, to calm the overactive immune response. Because conditions like pneumonitis (lung inflammation) or colitis (colon inflammation) can become dangerous if left untreated, patients are taught to report any new symptoms to their medical team immediately.

Additionally, these side effects can develop on a unpredictable timeline, sometimes appearing weeks into care, months after starting, or even after the treatment course is entirely complete.

Immunological Memory and Lasting Benefits

The most revolutionary aspect of immunotherapy is its ability to provide lasting benefits long after the treatment course has ended. Traditional chemotherapy only works while the drug is physically present in the patient’s body. Immunotherapy, however, works by building long-term immunological memory.

[Initial Immunotherapy Exposure] ──► T-Cell Antigen Re-education ──► Production of Memory T-Cells ──► Permanent Cancer Surveillance

This is the same biological principle that makes childhood vaccines effective for a lifetime. When engineered T-cells or checkpoint inhibitors help the immune system identify tumor antigens as an active threat, the body creates long-lived memory T-cells.

These specialized cells circulate in the bloodstream for years. If cancer cells attempt to grow again, these memory cells can quickly multiply and destroy the threat before it can spread.

This lifelong surveillance allows some patients with advanced melanoma or lung cancer to stop all treatment after one or two years and remain in complete remission. The potential for long-term safety without the need for ongoing medication marks a major shift in cancer care, offering many patients extended periods of health without the burden of continuous treatment.

Advanced considerations for immunotherapy treatment

Advanced considerations for immunotherapy involve leveraging biomarker testing for patient selection, understanding distinct modalities like CAR T-cell therapy, employing combination strategies, and exploring emerging frontiers in clinical research to optimize outcomes. Notably, these sophisticated approaches represent the shift towards highly personalized and dynamic cancer care, moving beyond broad-spectrum treatments to tailored interventions designed to maximize efficacy and overcome resistance.

As our understanding of the intricate dialogue between cancer cells and the immune system deepens, these advanced considerations become standard practice, allowing oncologists to make more informed decisions that are specific to a patient’s unique tumor biology and immune profile. This refined strategy is critical for improving patient survival rates and managing the unique side effects associated with harnessing the body’s own defense system.

Biomarker Testing and Molecular Selection Profiles

Advanced oncology relies heavily on biomarker testing to predict which patients will respond best to specific treatments. Rather than applying a uniform approach, clinicians use molecular profiling of blood and tissue samples to gain structural insights into a tumor’s unique traits and its interactions with the immune system. This targeted approach increases the likelihood of treatment success while protecting patients from the side effects of therapies that are unlikely to work for them.

                    [Molecular Profiling & Tissue Analytics]
                                       │
     ┌─────────────────────────────────┼─────────────────────────────────┐
     ▼                                 ▼                                 ▼
[PD-L1 Expression Assay]    [Tumor Mutational Burden]         [Mismatch Repair Status]
 ├── Core IHC stain scoring  ├── Total mutations per megabase  ├── Microsatellite tracking
 ├── Identifies tumor cloaks ├── Gauges neoantigen generation  ├── Tissue-agnostic approvals
 └── Directs anti-PD-1/PD-L1 └── Predicts T-cell visibility    └── pembrolizumab eligibility

PD-L1 Expression Levels and Immunohistochemistry (IHC)

Programmed death-ligand 1 (PD-L1) is a transmembrane protein frequently found on the surface of certain cancer cells. When PD-L1 binds to the PD-1 receptor on circulating T-cells, it transmits an inhibitory biochemical signal that tells the immune system to stand down.

To measure this, pathologists use Immunohistochemistry (IHC) staining on tumor tissue samples to calculate a Tumor Proportion Score (TPS) or a Combined Positive Score (CPS). These metrics assess the percentage of living tumor cells and infiltrating immune cells that display the target protein.

Testing a tumor sample for PD-L1 expression helps clinicians estimate how well a patient might respond to PD-1/PD-L1 inhibitors, as higher protein levels typically correlate with better outcomes in non-small cell lung cancer, head and neck squamous cell carcinomas, and advanced melanoma.

Tumor Mutational Burden (TMB) Metric Quantification

Tumor Mutational Burden measures the total number of non-inherited somatic mutations found within a megabase ($1\text{ Mb}$, or one million base pairs) of sequenced tumor DNA. Cancers with a high TMB—often defined as 10 or more mutations per megabase—frequently accumulate mistakes during cellular replication.

These genetic errors cause the cancer cells to produce a larger number of abnormal proteins called neoantigens. Because these neoantigens make the tumor appear foreign, the immune system can identify it more easily, making high-TMB tumors excellent targets for checkpoint inhibitors that release the brakes on T-cells.

Microsatellite Instability (MSI) and Mismatch Repair (MMR)

Microsatellites are short, repeating DNA sequences scattered throughout the human genome. A tumor classified as having high microsatellite instability (MSI-H) has a broken DNA mismatch repair (dMMR) system, which typically relies on specialized proteins like MLH1, MSH2, MSH6, and PMS2 to fix genetic mistakes. When this repair system is broken, mutations accumulate rapidly throughout the cells.

Like a high TMB, this instability makes the tumor highly immunogenic. Notably, MSI status serves as a tissue-agnostic biomarker, meaning therapies like pembrolizumab are approved to treat any solid MSI-H tumor, regardless of where it originated in the body.

CAR T-Cell Therapy vs. Immune Checkpoint Inhibitors

Chimeric Antigen Receptor (CAR) T-cell therapy represents a distinct shift from mass-produced therapies, earning it the clinical description of a “living drug.” While both CAR T-cell therapy and checkpoint inhibitors utilize the immune system, they differ fundamentally in their engineering, target diseases, and side effect profiles.

[Patient Leukapheresis] ──► Ex Vivo Viral Vector Engineering ──► In Vitro Expansion ──► Lymphodepleting Chemo ──► Re-Infusion

Manufacturing and Ex Vivo Engineering Workflows

The production of CAR T-cell therapy is a complex, patient-specific process. It begins with leukapheresis, where blood is drawn from the patient to isolate their native T-cells before the remaining blood components are returned to their circulation. These harvested immune cells are sent to a specialized laboratory, where a disarmed viral vector inserts a gene encoding a custom Chimeric Antigen Receptor (CAR) into the T-cells’ DNA.

This new receptor features an outer single-chain variable fragment designed to bind to specific cancer proteins, along with internal signaling domains (like CD3-zeta paired with 4-1BB or CD28) that trigger T-cell activation. These re-engineered cells are grown into the millions in an incubator.

Before the final infusion, the patient undergoes a brief course of lymphodepleting chemotherapy to clear out existing white blood cells, creating space and a supportive environment for the newly returned CAR T-cells to multiply and launch a targeted attack.

Comparing Treatment Modalities and Systemic Impacts

Synergistic Combination Therapy Paradigms

To overcome tumor resistance, modern oncology frequently combines immunotherapies with other treatment methods. The goal of combination therapy is to attack the cancer from multiple angles at once, turning unreactive tumors into targets that the immune system can easily recognize.

                           [Combination Therapy Matrix]
                                        │
     ┌───────────────────┬──────────────┴──────────────┬───────────────────┐
     ▼                   ▼                             ▼                   ▼
[Chemo Synergy]     [Targeted Synergy]            [Radiation Synergy] [Dual Checkpoints]
 ├── Causes tumor     ├── Alters the micro-        ├── Causes localized ├── Blocks distinct
 │   cell death          environment to expose         antigen release     │   brakes (PD-1
 │                       hidden cancer cells           (Abscopal effect)   │   and CTLA-4)
 └── Primes immune                                                         
     surveillance    └── Extends response duration └── Systemic attack └── Max T-cell punch

Immunotherapy Combined with Chemotherapy

Traditional chemotherapy can trigger immunogenic cell death. As cancer cells die, they break apart and release calreticulin, ATP, and high-mobility group box 1 (HMGB1) proteins into the surrounding tissue.

This process acts much like a natural vaccine, drawing dendritic cells to the tumor site to present these newly exposed antigens to T-cells. Following up with an immune checkpoint inhibitor amplifies this response, allowing re-energized T-cells to hunt down and eliminate any remaining cancer cells throughout the body.

Immunotherapy Combined with Targeted Therapy

Targeted therapies, such as small-molecule BRAF or MEK inhibitors used in melanoma, work by blocking specific signaling pathways inside cancer cells to rapidly shrink tumors. This process alters the tumor microenvironment by reducing the production of immunosuppressive chemicals and encouraging white blood cells to enter the area. Introducing immunotherapy alongside these drugs helps convert a quick initial response into long-term survival.

Immunotherapy Combined with Radiation Therapy

Radiation kills cancer cells locally while triggering a broader immune response known as the abscopal effect. The localized radiation breaks down tumor tissue, releasing tumor antigens and inflammatory signals that attract immune cells. Combining radiation with a systemic checkpoint inhibitor can turn a local immune reaction into a body-wide defense, allowing T-cells to destroy distant, untreated metastatic lesions.

Dual Immunotherapy Formulations

This approach pairs two different immunotherapy drugs, most commonly a PD-1/PD-L1 inhibitor with a CTLA-4 inhibitor (such as combining nivolumab with ipilimumab). Because these two molecules control different checkpoints in the immune response—CTLA-4 works early on in the lymph nodes, while PD-1 works later within the tumor itself—blocking both simultaneously provides a more powerful activation of T-cells than using either drug on its own.

Next Frontiers in Immuno-Oncology Research

The field of immunotherapy continues to advance rapidly, with clinical trials exploring new ways to bypass resistance and expand treatment options to a wider variety of cancers.

[Tumor Gene Sequencing] ──► Neoantigen Identification ──► Synthetic mRNA Vaccine ──► Tailored Patient Attack

Personalized Neoantigen Vaccines

Unlike preventative vaccines, therapeutic cancer vaccines are custom-made to treat existing disease. Clinical researchers sequence a patient’s healthy tissue and tumor cells to identify the exact mutations producing unique neoantigens.

Using this genetic data, scientists manufacture a personalized mRNA or peptide vaccine tailored to the patient’s specific tumor profile. When injected, the vaccine trains the immune system to recognize these unique markers, mounting an attack that targets only the cancer cells while leaving healthy tissue unharmed.

Microbiome Manipulation

A growing body of research shows that the trillions of microbes living in the human gut—the microbiome—play a significant role in how well checkpoint inhibitors work. Certain gut bacteria help promote a stronger anti-tumor immune response.

Current clinical trials are testing whether modifying the microbiome through targeted probiotics, dietary changes, or fecal microbiota transplants (FMT) from healthy donors can help non-responsive patients benefit from immunotherapy.

Next-Generation Checkpoints and Agonists

The success of early therapies has led researchers to look for other pathways that control the immune system. Scientists are now developing drugs to block newer inhibitory checkpoints, such as LAG-3, TIM-3, and TIGIT, which represent different brakes on immune cells.

At the same time, researchers are testing immune agonists—molecules designed to stimulate co-stimulatory receptors like OX40, GITR, or CD40. These act as gas pedals for the immune response, further boosting the body’s ability to fight tumors.

Conclusion

Immunotherapy is an important cancer treatment that uses the body’s immune system to help fight cancer. It may work by boosting immune responses, helping immune cells find cancer, or blocking cancer’s ability to hide from immune attack.

While some patients have strong and lasting responses, others may not benefit, which is why treatment decisions depend on cancer type, biomarkers, stage, previous treatments, and overall health. If you are considering immunotherapy, ask your oncology team about expected benefits, possible immune-related side effects, treatment schedule, monitoring, and what symptoms should be reported right away.

Read more: 10 Causes of Peripheral Vision Changes and What They May Mean

Frequently Asked Questions

1. What is immunotherapy?

Immunotherapy is a cancer treatment that helps the immune system fight cancer. It may stimulate the immune system, help immune cells recognize cancer cells, or use lab-made substances that act like natural immune system parts. Some immunotherapies work broadly, while others are designed to target specific cancer features. The best option depends on the cancer type, test results, and the patient’s overall condition.

2. How is immunotherapy different from chemotherapy?

Chemotherapy directly attacks fast-growing cells, including cancer cells and some healthy cells. Immunotherapy works differently by helping the immune system identify and attack cancer. This means side effects can also differ, since immunotherapy may cause the immune system to inflame healthy organs. Some patients receive immunotherapy alone, while others receive it with chemotherapy, radiation, surgery, or targeted therapy.

3. What types of cancer can immunotherapy treat?

Immunotherapy can treat several cancers, but it is not appropriate for every cancer or every patient. It may be used in melanoma, lung cancer, kidney cancer, bladder cancer, head and neck cancers, lymphoma, leukemia, and some colorectal cancers, among others. Doctors may test tumors for biomarkers such as PD-L1, MSI-H, dMMR, or specific genetic features to see whether immunotherapy may help. Treatment recommendations depend on cancer stage, prior therapy, tumor biology, and overall health.

4. What are possible side effects of immunotherapy?

Immunotherapy can cause side effects when the immune system becomes too active and attacks healthy tissues. Symptoms may include rash, diarrhea, fatigue, cough, shortness of breath, hormone changes, liver inflammation, or kidney problems. Some side effects are mild, but others can become serious if not treated early. Patients should report new or worsening symptoms promptly, even if they seem unrelated to cancer treatment.

5. How long does immunotherapy take to work?

The time it takes for immunotherapy to work varies from person to person. Some patients may show improvement within weeks or months, while others may need several scans before doctors can judge the response clearly. In some cases, tumors may appear larger at first because immune cells are entering the tumor area. The oncology team will use imaging, lab tests, symptoms, and clinical judgment to decide whether treatment is working.

Sources

1. Immunotherapy for Cancer (National Cancer Institute)
2. What Is Immunotherapy? (American Cancer Society)
3. Cancer Treatment: Immunotherapy (Mayo Clinic)
4. What Is Cancer Immunotherapy? (Mayo Clinic Comprehensive Cancer Center)
5. Immunotherapy and Its Side Effects (Cancer Research UK)
6. What Is Immunotherapy? (Cancer Research Institute)
7. Side Effects of Immunotherapy: What to Know (Cancer Research Institute)